Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
Syntara Limited
SNTSyntara Limited operates as a clinical-stage drug development company that focuses on blood-related cancers in Australia. The company's lead product candidate is SNT-5505, which is in Phase 2 trial to treat myelofibrosis, myelodysplastic syndrome, hepatocellular carcinoma, and pancreatic cancer, as well as scar prevention. It also develops SNT-4728 in Phase 2 trial for the treatment of neurodegenerative diseases comprising isolated rapid eye movement sleep behavior disorder (IRBD) and Parkinson's disease; SNT-5382, which is a selective lysyl oxidase-like 2 inhibitor in Phase 1 trial to treat chronic fibrosis; and SNT-8370 for the treatment of inflammation. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia. Address: 20A Rodborough Road, Frenchs Forest, NSW, Australia, 2086
Analytics
WallStreetin tavoitehinta
0.15 AUDP/E-suhde
–Osinkotuotto
–Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Avainluvut SNT
Osinkoanalytiikka SNT
Osinkojen kasvu 5 vuoden aikana
–Jatkuva kasvu
–Maksusuhde 5 vuoden keskiarvo
–Osinkohistoria SNT
Osakkeen arvostus SNT
Talousasiat SNT
Tuloksia | 2019 | Dynamiikka |